High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial (2017)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1373/clinchem.2016.264788
- Subjects: BIOMARCADOR; TROPONINA; DOENÇAS CARDIOVASCULARES; ARTERIOSCLEROSE
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2017
- Source:
- Título do periódico: Clinical Chemistry
- ISSN: 0009-9147
- Volume/Número/Paginação/Ano: v. 63, n. 1, p. 307-315, 2017
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
EISEN, Alon et al. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clinical Chemistry, v. 63, n. 1, p. 307-315, 2017Tradução . . Disponível em: https://doi.org/10.1373/clinchem.2016.264788. Acesso em: 23 maio 2024. -
APA
Eisen, A., Bonaca, M. P., Scirica, B. M., White, H. D., Tendera, M., Dellborg, M., et al. (2017). High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clinical Chemistry, 63( 1), 307-315. doi:10.1373/clinchem.2016.264788 -
NLM
Eisen A, Bonaca MP, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KAA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial [Internet]. Clinical Chemistry. 2017 ; 63( 1): 307-315.[citado 2024 maio 23 ] Available from: https://doi.org/10.1373/clinchem.2016.264788 -
Vancouver
Eisen A, Bonaca MP, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KAA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial [Internet]. Clinical Chemistry. 2017 ; 63( 1): 307-315.[citado 2024 maio 23 ] Available from: https://doi.org/10.1373/clinchem.2016.264788 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1373/clinchem.2016.264788 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
